clinical trial · NCT04623775
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb·phase2·completed·n = 468
Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerMetastatic Non-small Cell Lung CancerNivolumabRelatlimabCarboplatinCisplatinPaclitaxelNab-PaclitaxelPemetrexed
brief summary
The purpose of this study is to assess the safety profile of relatlimab plus nivolumab in combination with platinum doublet chemotherapy (PDCT) and to determine if nivolumab plus relatlimab in combination with PDCT improves overall response rate (ORR) when compared to nivolumab plus PDCT in participants with previously untreated Stage IV or recurrent non-small cell lung cancer (NSCLC).
started
Feb 17, 2021
primary completion
Jan 11, 2024
completion
May 6, 2026
last updated
Jun 18, 2026
official title
A Phase 2 Randomized Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol